M. Cazzola (Rome, Italy), P.J. Barnes (London, United Kingdom)
Once-daily glycopyrronium improves lung function and reduces exacerbations in severe-to-very severe COPD patients: The SPARK study
J. A. Wedzicha, M. Decramer, J. H. Ficker, A. FowlerTaylor, P. D'Andrea, C. Arrasate, H. Chen, D. Banerji (London, United Kingdom; Leuven, Belgium; Nuernberg, Germany; East Hanover, United States Of America)
|  |
Dual bronchodilation with once-daily QVA149 reduces exacerbations, improves lung function and health status versus glycopyrronium and tiotropium in severe-to-very severe COPD patients: The SPARK study
J. A. Wedzicha, M. Decramer, J. H. Ficker, D. Niewohner, T. Sandström, A. FowlerTaylor, D. Banerji (London, United Kingdom; Leuven, Belgium; Nuernberg, Germany; Umea, Sweden; Minneapolis, East Hanover, United States Of America)
| |
QVA149 reduces COPD exacerbation rate in various subgroups of patients: The SPARK study
J. H. Ficker, J. A. Wedzicha, M. Decramer, A. FowlerTaylor, P. D'Andrea, C. Arrasate, H. Chen, D. Banerji (Nuernberg, Germany; London, United Kingdom; Leuven, Belgium; East Hanover, United States Of America)
|   |
Efficacy and safety of abediterol (LAS100977) in patients with COPD: Phase II, randomised, crossover study
J. Beier, H. Pujol, B. Seoane, E. Jimenez, C. Astbury, S. Ruiz, G. de Miquel (Wiesbaden, Germany; Barcelona, Spain)
| |
Improvement in COPD symptoms with aclidinium bromide vs placebo and tiotropium: A phase IIIb study
J. Beier, A. M. Kirsten, R. Mroz, R. Segarra, F. Chuecos, C. Caracta, E. Garcia Gil (Wiesbaden, Grosshansdorf, Germany; Bialystok, Poland; Barcelona, Spain; Jersey City, United States Of America)
| |
Efficacy and safety of aclidinium bromide vs placebo and tiotropium in COPD: A phase IIIb study
J. Beier, A. M. Kirsten, R. Mroz, R. Segarra, F. Chuecos, C. Caracta, E. Garcia Gil (Wiesbaden, Grosshansdorf, Germany; Bialystok, Poland; Barcelona, Spain; Jersey City, United States Of America)
| |
A phase II, randomised, placebo controlled trial of 12 weeks treatment with an oral p38 inhibitor in patients with COPD on a background of ICS/LABA
R. Fogel, K. Shields, J. Christensen, J. Ribbing, G. Langdon, C. Perros-Huguet, N. Clarke (Collegeville, United States Of America)
| |
Lung function efficacy of olodaterol QD delivered via Respimat® in COPD patients: Results from two 48-week studies
G. Ferguson, G. Feldman, P. Hofbauer, A. Hamilton, L. Allen, L. Korducki, P. Sachs (Livonia, Spartanburg, Ridgefield, Stamford, United States Of America; Weinheim, Germany; Burlington, Canada)
| |